Keep Our Promise to America's Children and Teachers Act or the Keep Our PACT Act This bill provides funding through FY2031 for grant programs operated by local educational agencies to provide supplementary educational and related services to low-achieving students and other students who attend elementary and secondary schools with relatively high concentrations of students from low-income families. Additionally, the bill permanently reauthorizes the grant program to assist states and outlying areas in providing special education and related services to children with disabilities.
Dropbox Access Act This bill requires each state to provide in each county secured drop boxes at which individuals may drop off their completed absentee ballots for federal elections. Specifically, the bill requires these drop boxes to be (1) available beginning 45 days before the election; (2) accessible to individuals with disabilities and individuals with limited proficiency in the English language; (3) accessible by public transit; (4) available during all hours of the day; and (5) located in all communities within the county, including rural communities and on tribal lands. States must also post the requirements for absentee ballots to be counted and tabulated in the election. Further, the bill outlines additional requirements that a state must meet in determining the number and location of drop boxes.
Taking Account of Institutions with Low Operation Risk Act or the TAILOR Act This bill requires federal financial regulatory agencies to (1) tailor any regulatory actions so as to limit burdens on the institutions involved, with consideration of the risk profiles and business models of those institutions; and (2) report to Congress on specific actions taken to do so, as well as on other related issues. The bill's tailoring requirement applies not only to future regulatory actions but also to regulations adopted within the last seven years.
This bill requires the President to notify Congress and the public of executive orders relating to energy policy before issuing such orders.
This bill requires the President to provide Congress with certain information at least 30 days before issuing an executive order related to abortion. Before issuing an abortion-related executive order, the President shall provide Congress with (1) the executive order text, (2) a list of the federal laws affected, (3) information about how the President is working within the parameters of federal law and the Constitution, (4) information about how the executive order will be accomplished, and (5) a list of all the individuals and entities that the President engaged with before issuing the order.
Pandemic Emergency Manufacturing Act of 2021 This bill establishes within the Department of Health and Human Services (HHS) an Emergency Office of Manufacturing for Public Health to manufacture and distribute medical products to address COVID-19 (i.e., coronavirus disease 2019) or medical products that are on shortage or vulnerable to shortage. The office must (1) obtain the rights to manufacture the applicable medicines, ingredients, diagnostic tests, medical devices, personal protective equipment, and supplies; (2) manufacture or contract to manufacture such items; and (3) construct, or enter into construction contracts for, facilities to manufacture certain medicines, such as vaccines. HHS may issue involuntary licenses allowing the office to make, use, sell, import, or export an invention related to an applicable drug, biological product, or device and to use clinical trial data and confidential information. Such a license must provide the rights holder with reasonable compensation. The office must (1) provide such COVID-19 products at no cost to federal, state, local, and other health programs and certain domestic health care providers and suppliers; (2) offer COVID-19 products at cost to other commercial and international entities; and (3) offer other medical products to entities at a fair price, based on cost and other considerations. The office shall prioritize the manufacture of certain COVID-19 products and meet manufacturing timelines specified in the bill.
Premium Relief Act of 20 21 This bill establishes and provides funding through FY2024 for the Patient and State Stability Fund, which shall be used to support specified state efforts to increase access to health-insurance coverage and help stabilize the individual market. Specifically, states may use the funds to (1) lower the cost for individuals to purchase coverage, (2) lower out-of-pocket costs for individuals with insurance, (3) pay health care providers, (4) cover or provide additional specified services, and (5) otherwise increase coverage options and stabilize premiums in the state's insurance market. If a state does not apply for funds under the program, the Centers for Medicare & Medicaid Services, in consultation with the state, must use the funds to stabilize premiums by partially reimbursing insurers for claims in a specified cost range. The bill also revises the grace period that health insurers must provide to recipients of premium subsidies before discontinuing health coverage for nonpayment of premiums. The grace period is shortened from 3 months to 30 days unless state law includes an applicable grace period.
Ensuring Vaccination and Treatment Affordability Act This bill requires COVID-19 (i.e., coronavirus disease 2019) vaccines and treatment, as well as treatment for conditions that may complicate COVID-19 treatment, to be covered without cost-sharing under the Children's Health Insurance Program (CHIP) and Medicaid. Additionally, the bill includes vaccines for COVID-19 in the Vaccines for Children (VFC) Program. The VFC Program provides free vaccinations to individuals 18 years of age or younger who are uninsured or underinsured (i.e., with limited or no insurance for vaccines), are eligible for Medicaid, or are American Indians or Alaskan Natives.
Reciprocity Ensures Streamlined Use of Lifesaving Treatments Act of 2021 This bill establishes a reciprocal marketing approval process that allows for the sale of a drug, biological product, or medical device that has not been approved by the Food and Drug Administration (FDA) if the product is approved for sale in another country and there is an unmet need. Specifically, the bill requires the product's sponsor to demonstrate, among other things, that (1) the product has been approved in one of the specified countries, (2) neither the FDA nor any of the specified countries have withdrawn approval for the product because of safety or effectiveness concerns, and (3) there is a public health or unmet medical need for the product. The FDA may decline approval if the FDA determines that the product is not safe or effective. The FDA may condition reciprocal approval on the conduct of postmarket studies. The FDA must issue a decision on whether to grant a request for reciprocal marketing approval within 30 days of receiving the request. Congress may pass a joint resolution to grant reciprocal marketing approval of a product that the FDA declines to approve through the reciprocal process.
Equal Access to Care Act This bill temporarily authorizes a health care provider who is physically located and duly licensed in one state to provide telehealth services to individuals in one or more additional states in which the provider is not licensed during the COVID-19 (i.e., coronavirus disease 2019) emergency period.
Unconscionable Pricing Act This bill makes it unlawful for any person to sell, rent, or lease an emergency supply at an unconscionable price during a federally-declared emergency. A price is unconscionable if (1) it exceeds 10% of the average price for the same or similar emergency supply during the 30 days before the emergency was declared, and (2) such price increase is not related to the reasonable costs incurred to sell or rent the supply. The bill provides authority for the Federal Trade Commission and state attorneys general to enforce the requirements of this bill.
Emergency Support for Substance Use Disorders Act This bill requires the Substance Abuse and Mental Health Services Administration to award grants to states, other jurisdictions, and community-based entities for harm reduction activities to address drug misuse during the COVID-19 (i.e., coronavirus disease 2019) pandemic.
